Skip to main content

Advertisement

SpringerLink
Log in

Role of 18F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer — 2 Case Reports

  • Case Report
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Drug induced pulmonary toxicity is not uncommon with the use of various chemotherapeutic agents. Cyclophosphamide is a widely used chemotherapeutic drug in the treatment of breast cancer. Although rare, lung toxicity has been reported with cyclophosphamide use. Detection of bleomycin induced pulmonary toxicity and pattern of 18F-fluorodeoxyglucose (18F-FDG) uptake in lungs on fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) has been elicited in literature in relation to lymphoma. However, limited data is available regarding the role of 18F-FDG PET-CT in monitoring drug induced pulmonary toxicity in breast cancer. We here present two cases of cyclophosphamide induced drug toxicity. Interim 18F-FDG PET-CT demonstrated diffusely increased tracer uptake in bilateral lung fields in both these patients. Subsequently there was resolution of lung uptake on 18F-FDG PET-CT scan post completion of chemotherapy. These patients did not develop significant respiratory symptoms during chemotherapy treatment and in follow up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kazama T, Faria SC, Uchida Y, Ito H, Macapinlac HA. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med. 2008;22:111–4.

    Article  PubMed  Google Scholar 

  2. Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk & Lymphoma. 2009; 50:904–11.

  3. Song BI, Lee SW, Lee HJ, Kang S, Jeong SY, Seo JH et al. Rituximab-induced pneumonitis on F-18 FDG PET/CT in patient with non-Hodgkin lymphoma. Clin Nucl Med. 2010;35:601–3.

    Article  PubMed  Google Scholar 

  4. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321–40.

    CAS  PubMed  Google Scholar 

  5. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am Rev Respir Dis. 1986;133:488–505.

    CAS  PubMed  Google Scholar 

  6. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17:372–9.

    Article  CAS  PubMed  Google Scholar 

  7. Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M et al. Acute lung injury associated with 5-fluorouracil and oxaliplatin combined chemotherapy. Eur Respir J. 2001;18:243–5.

    CAS  PubMed  Google Scholar 

  8. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154:1851–6.

    Article  CAS  PubMed  Google Scholar 

  9. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000;20:1245–9.

    Article  CAS  PubMed  Google Scholar 

  10. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71:301–26.

    Article  PubMed  Google Scholar 

  11. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133:528–38.

    Article  CAS  PubMed  Google Scholar 

  12. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–24.

    Article  CAS  PubMed  Google Scholar 

  13. Wagnerae T. Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs. Cancer Imaging. 2012; 12:7–12.

  14. Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med. 2009;50:538–45.

    Article  PubMed  Google Scholar 

  15. Prakash P, Kalra MK, Sharma A, Shepard JA, Digumarthy SR. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. AJR Am J Roentgenol. 2010;194:231–6.

    Article  PubMed  Google Scholar 

  16. Yu JQ, Kumar R, Xiu Y, Alavi A, Zhuang H. Diffuse FDG, uptake in the lungs in aspiration pneumonia on positron emission tomographic imaging. Clin Nucl Med. 2004;29:567–8.

    Article  PubMed  Google Scholar 

  17. Rodrigues RS, Miller PR, Bozza FA, Marchiori E, Zimmerman GA, Hoffman JM et al. FDG-PET in patients at risk for acute respiratory distress syndrome: a preliminary report. Intensive Care Med. 2008;34:2273–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, A.I.I.M.S, New Delhi, India

    Sameer Kamalakar Taywade, Rakesh Kumar & Chandrasekhar Bal

  2. Department of Medical Oncology, A.I.I.M.S, New Delhi, India

    Sainath Bhethanabhotla

Authors
  1. Sameer Kamalakar Taywade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rakesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sainath Bhethanabhotla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chandrasekhar Bal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rakesh Kumar.

Ethics declarations

Conflict of Interest

Authors Sameer Kamalakar Taywade, Chandrasekhar Bal and Rakesh Kumar declare that they have no conflict of interest.

The manuscript has not been published before or is not under consideration for publication anywhere else and has been approved by all co-authors.

Ethical Statement

Manuscript contains a statement that the study was approved by an institutional review board or equivalent and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All subjects in the study gave written informed consent or the institutional review board waived the need to obtain informed consent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taywade, S.K., Kumar, R., Bhethanabhotla, S. et al. Role of 18F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer — 2 Case Reports. Nucl Med Mol Imaging 50, 261–265 (2016). https://doi.org/10.1007/s13139-015-0388-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-015-0388-3

Keywords

Search

Navigation